Women Face Testosterone Prescription Denials After 146% Surge in Use
Updated
Updated · Devdiscourse · Sep 15
Women Face Testosterone Prescription Denials After 146% Surge in Use
1 articles · Updated · Devdiscourse · Sep 15
Summary
A 146% jump in testosterone prescriptions for women from January 2023 to July 2026 has collided with pharmacy and insurer denials, leaving many unable to access treatment for menopause-related symptoms.
No FDA-approved testosterone product exists for women in the United States, forcing doctors and patients into off-label prescribing that many pharmacies and health plans refuse to honor.
Low sexual desire has been a key reason for the therapy’s growing use, even as uncertainty persists over which patients benefit most and what risks long-term treatment may carry.
The FDA is preparing to review testosterone’s use and safety in women, while ongoing clinical trials and agency workshops aim to shape clearer rules for prescribing and coverage.